Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients
Introduction With the introduction of FLT3 inhibitors in recent years, the presence of FLT3 mutation in newly diagnosed acute myeloid leukemia (AML) patients has become more important. it was observed that the addition of Midostaurin to remission induction and consolidation chemotherapy, brought a 2...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nizameddin KOCA
2021-03-01
|
| Edice: | Turkish Journal of Internal Medicine |
| Témata: | |
| On-line přístup: | https://dergipark.org.tr/tr/download/article-file/1552683 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|